Home » Health » Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in U.K., but less against new South African variant - MarketWatch

By Sugus Parmin Friday, January 29, 2021 Health

Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in U.K., but less against new South African variant - MarketWatch

Bagikan Berita Ini

0 Response to "Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in U.K., but less against new South African variant - MarketWatch"

Search

Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in U.K., but less against new South African variant - MarketWatch

0 Response to "Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in U.K., but less against new South African variant - MarketWatch"

Post a Comment